UCB pulls out of epratuzumab licensing deal with Immunomedics
US biotech firm Immunomedics (Nasdaq: IMMU) revealed today that it had received notice from Belgian drugmaker UCB (Euronext: UCB) terminating the May 2006 development, collaboration and license agreement for epratuzumab for all non-cancer indications worldwide.
Immunomedics’ shares fell 1.9% to 2.07 euros on Thursday but recovered to $2.10, a rise of 1.45% today.
Under an amended collaboration in 2011, UCB agreed to pay Immunomedics $30 million up front; an additional $30 million if UCB exercised its right to sublicense, plus additional unspecified payments tied to achieving regulatory and sales milestones (The Pharma Letter December 29, 2011). The termination follows the disclosure in July that epratuzumab failed two Phase III trials (TPL July 28, 2015). Under the terms of the agreement, the companies will now begin the transition process in a timely and orderly fashion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze